TRPV1 inhibitor
Pre-clinical- Indications
- Perioperative hypothermia
Company intelligence / Profile preview
Catalina Pharma
Arizona, United Statescatalinapharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Catalina Pharma is developing a TRPV1 inhibitor for the treatment of anesthesia-induced hypothermia. The company is repurposing a failed pain relief treatment to address surgical hypothermia[1][4].
- Therapeutic areas
- Other
- Modalities
- Small molecules (TRPV1 inhibitor)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Arizona
Beyond the preview
Go deeper on Catalina Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catalina Pharma.